---
title: 'Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute
  cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled,
  phase 2b trial'
date: '2024-12-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39706632/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241221170703&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Spinal cord injury results in permanent neurological impairment
  and disability due to the absence of spontaneous regeneration. NG101, a recombinant
  human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting
  neural repair and motor recovery in animal models of spinal cord injury. We aimed
  to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute
  cervical traumatic spinal cord ...'
disable_comments: true
---
BACKGROUND: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord ...